We review Pneumocystis carinii pneumonia (PCP) in patients in the developing world (i.e., Africa, Asia, the Philippines, and Central and South America) who have acquired immunodeficiency disease (AIDS). During the first decade of the AIDS pandemic, PCP rarely occurred in African adults. More recent reports have noted that PCP comprises a significantly greater percentage of cases of pneumonia than it did in the past. This trend dramatically contrasts with that observed in industrialized nations, where a reduction in the number of cases of PCP has occurred as a result of the widespread use of primary P. carinii prophylaxis and highly active antiretroviral therapy. Throughout the developing world, the rate of coinfection with Mycobacterium tuberculosis and PCP is high, ranging from 25% to 80%. Initiation of treatment when PCP is in an advanced stage may account for the high mortality rates (20%-80%) associated with pediatric PCP in the developing world.
Among patients with AIDS, Pneumocystis carinii pneumonia (PCP) has been noted to occur less frequently in patients in developing regions than in those in industrialized countries [1] [2] [3] . Early autopsy reports showed that tuberculosis, bacteremia due to nontyphoid Salmonella species and pneumococci, and HIV wasting syndrome occurred more often among African patients with AIDS than among patients with AIDS living in developed countries [4] . Autopsy reports also showed that disseminated infection with Mycobacterium avium complex and PCP occurred less frequently among HIV-infected patients in Africa than among such patients in developed countries [4] . Other studies showed that tuberculosis was the diagnosis most frequently given to selected HIV-infected patients who had abnormal chest radiography findings that were consistent with PCP [5] . Citing these reports, the authors of texts on tropical medicine concluded that tuberculosis was the major HIVassociated illness in the developing world and that PCP was uncommon [1] [2] [3] . Additional factors, such as lack of standardization of the CD4 cell count of patients included in the series, also are likely to influence the percentage of patients infected with PCP. For example, differences in the stage of HIV infection would influence the prevalence of PCP, particularly in studies that include patients with respiratory symptoms who have a CD4 cell count that is greater than that associated with the likely occurrence of PCP. Although the chronological order and states of immunodeficiency at which different opportunistic infections occur in developing regions have not been defined [1] , there is no evidence to support speculation that PCP may occur at an earlier stage of infection among individuals in developing countries than among those in industrialized countries [39] . Finally, differences in the prevalence of P. carinii in the environment, differences in susceptibility that are associated with race, and ecological factors that result in exposure to P. carinii may also influence the prevalence of PCP. The individual studies that address PCP in patients with AIDS in various regions throughout the developing world are summarized in the text below.
Pediatric studies. Studies performed during the past decade that used different diagnostic techniques have shown that P. carinii causes respiratory symptoms in a variable percentage of children (table 1) . One retrospective study from Malawi that was performed in 1995 [8] showed that PCP accounted for pneumonia in only 8% of children, 40% of whom were not infected with HIV. Two subsequent prospective African studies that were performed in 1998 (in South Africa) [6] and 1996 (in Malawi) [7] , and that used diagnostic methods involving induced sputum specimens, showed that PCP was present in 10% and 11% of cases, respectively. A prospective South African study of hospitalized patients conducted in 1998-1999 [12] , which used diagnostic techniques that involved the use of induced sputum specimens and direct fluorescent antibody staining, showed that PCP accounted for 49% of cases. In contrast, a study from the same group of investigators at the same hospital that used clinical criteria only to diagnose PCP in 1997-1998 reported a lower percentage of PCP (20%) [13] . Finally, a study from Thailand showed that PCP diagnosed on the basis of clinical criteria occurred in only 40% of patients with AIDS who were followed longitudinally for 9 years [14] .
Postmortem studies of HIV-infected children who died of any cause or who died exclusively of a respiratory illness have noted a higher percentage of cases due to PCP than did the trials summarized in the preceding paragraph. In one report, PCP accounted for 52% of patients with pulmonary infiltrates who died in an intensive care setting in South Africa during 1992-1993 [11] . Another study showed that PCP was present in 66% of patients in Thailand who had pulmonary infiltrates and who died before 1994 [15] . Additional studies that have reported postmortem findings for all deaths due to HIVincluding those not resulting from HIV-associated pulmonary disease-have shown that the percentage of PCP cases is lower than that noted in series restricted to patients whose deaths were due to pulmonary abnormalities. For example, one study from Zimbabwe [9] showed that 16% of patients who died at home during 1991-1992 had PCP, whereas another study from Cote d'Ivoire [10] showed that 14% of patients who died during this period died of PCP.
Early adult studies performed during or before 1992. Six clinical studies initiated and performed during the early period of the AIDS pandemic showed that P. carinii was an uncommon cause of pneumonia in HIV-infected African adults. One study performed during this period showed that Mycobacterium tuberculosis and other bacteria were more frequent causes of pneumonia than was PCP [40] . Two prospective studies, one conducted in 1990 in Rwanda [17] and the other conducted in 1989-1991 in Tanzania [18] , showed that PCP accounted for 4%-5% of cases of pneumonia, respectively (table 2). Two other prospective studies from Zambia, which were performed in 1990 [19] and 1988 [23] , and another study from Congo, which was performed before 1990 [21] , showed that PCP accounted for 9%-15% of cases of pneumonia. An additional study performed in Zambia during 1986-1987 [22] reported a higher percentage of PCP (22%) than did other studies conducted during this period.
Three clinical studies from the Americas showed that the prevalence of PCP among patients with AIDS during the early period of the pandemic was higher than the prevalence indicated in reports from Africa. One prospective Brazilian study conducted in 1988 showed that P. carinii caused 43% of cases of pneumonia in HIV-infected patients [36] . A retrospective Haitian study conducted in 1982 used standard diagnostic tests to show that P. carinii caused pneumonia in 35% of patients with AIDS [30] . In addition, a Brazilian study in 1989, which also used sensitive diagnostic tests, showed that PCP was the cause of 24% of cases of pneumonia [38] .
Five autopsy studies reported from Africa and the Americas noted that the prevalence of PCP cases was 3%-25% during this period. One study of patients in Cote d'Ivoire who died of any cause during 1989-1991 [4] and another study of patients in the same country who died of pneumonia in 1989 [20] showed that the prevalence of PCP was 3% and 13%, respectively. In the latter series, one-third of the patients were not infected with HIV. One Mexican study performed in 1984-1989 [33] and another Brazilian study performed in 1981-1985 [37] reported a PCP prevalence of 24% and 13%, respectively, among patients who died of any cause.
Studies of adults performed during or after 1992. More recent clinical studies that used sensitive methods to diagnose PCP have shown that P. carinii accounts for a greater percentage of cases of pneumonia among African adult HIV-infected patients than had been noted in earlier reports. One South African retrospective study that used BAL and monoclonal antibody methods for patients who had pneumonia diagnosed during 1988-1993 showed that PCP accounted for 43% of episodes [16] . In another prospective study that used similar diagnostic methods for patients who had pneumonia diagnosed during 1992-1993 in Zimbabwe, 33% of patients had PCP [5] . In a retrospective study that was conducted in a country (Thailand) on a different continent during this period and that also used BAL and monoclonal staining methods, PCP accounted for 28% of cases of pneumonia during 1992-1994 [28] .
In Asia, 3 additional descriptive studies of patients with respiratory symptoms, for which the diagnostic methods used to detect PCP were not specified or for which clinical criteria alone were used, reported rates that are lower than those reported in the studies mentioned in the preceding paragraph. For example, in one large study conducted in Thailand in 1994 [26] , and in a study from the Philippines [29] performed during 1985-1993, PCP accounted for 30% of episodes [26] . In another study performed during 1989-1998 in Thailand (in which the diagnosis was made without laboratory confirmation), PCP accounted for 5% of cases of pneumonia [24] . Finally, in a South Korean study performed during 1995-1998, the prevalence of PCP was 10% [25] . Only one autopsy study of HIVinfected patients was conducted during this period; it reported that 13% of patients who died with pulmonary infiltrates during 1986-1996 had PCP [27] .
Four South or Central American studies that investigated the prevalence of PCP recently have been performed. Each study used diagnostic methods of varying sensitivities and reported broadly variable PCP percentages and rates (defined as the number of new cases of PCP in a specified time period for the population at risk). One Panamanian study from 1995 that used sensitive diagnostic methods showed that PCP occurred in 84% of patients with respiratory symptoms [32] . A Central American study conducted during 1990-1995 reported that PCP was present in 16% of patients with respiratory symptoms [31] . A prospective study of 150 patients from Chile reported an incidence of 9.1 PCP events per 100 patient-years [34] . A Brazilian longitudinal study performed during 1991-1995 reported a PCP rate of 18% among HIV-infected patients without AIDS who were followed for 5 years [35] .
Possible reasons for increases in the number of cases of PCP in Africa and other developing countries. PCP now accounts for a substantial percentage of cases of pneumonia in both adult and pediatric HIV-infected patients with respiratory symptoms in Africa and in other regions in the developing world. It remains speculative whether the trend toward an increase in the proportion of African cases, as illustrated in figure 1 , denotes a true increase in the prevalence of PCP or whether the early reports underestimated the actual prevalence. If the latter is correct, the observed increase in PCP prevalence would be an artifact of the lack of standardization of inclusion criteria, rates of PCP prophylaxis, and diagnostic tests used across studies. In the absence of standardized studies to compare these 2 possibilities directly, only indirect evidence is available to support the possibility that the prevalence of PCP may be increasing. For example, several early studies that reported low prevalences of PCP (9%-22%) used sensitive diagnostic methods, such as BAL with toluidine blue stain [19, 21, 22] . In addition, early autopsy studies that involved patients who died in a respiratory ward and the use of sensitive staining methods also reported low percentages of PCP [20] .
Decrease in the incidence of PCP in the developed world. In contrast to the reported incidence of PCP in the developing world, the reported incidence of PCP in the developed world has undergone a significant decrease during the course of the epidemic. Both the use of P. carinii prophylaxis and, more recently, the use of HAART have contributed to this decrease. One US study of patients with CD4 counts of !100 cells/mm 3 showed that the incidence of PCP decreased from 13 cases per 100 patient-years in 1994 to 3 cases per 100 patient-years in 1997. Because the rates of PCP prophylaxis remained constant (92%) during the study period, HAART was considered to play the key role in the reduction of PCP incidence [41] . During this time, there was no significant change in the frequency of administration of PCP prophylaxis, a finding that confirms that HAART was essential to the reduction in the incidence of PCP. In addition, a Swiss study showed a 30% reduction in the incidence of PCP during 1995-1997 (from 2.35 episodes per 100 patient-years to 0.22 episodes per 100 patient-years) [42] . Despite these therapies, PCP remained the most common AIDS-defining opportunistic infection in the United States [43] , accounting for 39% of cases in 1997.
COMPARISON OF CLINICAL FEATURES OF PCP IN DEVELOPING COUNTRIES WITH THOSE IN INDUSTRIALIZED COUNTRIES
Comments on the clinical features, radiological patterns, or laboratory abnormalities associated with PCP in developing countries are restricted as a result of the limited number of studies that describe these features. Nevertheless, in the 5 articles in which clinical features are reported, respiratory rates range from 30-80 breaths per min (tables 1 and 2). In addition, the Sao 2 saturation is low (60% and 82%) in the 2 articles in which it is reported [7, 8] , and the Po 2 is low (70 mm Hg) in the single article in which it is recorded, suggesting the presence of an advanced or severe stage of PCP [28] .
Only a minority of the reports include information on CD4 cell counts, and only one of these studies specifies the CD4 cell counts of patients on the basis of the presence of PCP (14 cells/ mm 3 ) [4] . The mean CD4 cell counts of all patients in adult and pediatric series that reported CD4 cell counts are 871, 134, 324, 22, and 16 cells/mm 3 ; the corresponding prevalence of PCP in each of these series was 10%, 33%, 27%, 49%, and 10% (tables 1 and 2). Thus, by including patients with CD4 cell counts greater than the range of CD4 cell counts associated with the expected occurrence of PCP, these series underestimate the true prevalence of PCP in the population that is at risk for this infection. The possibility that PCP may occur at an earlier stage of infection among individuals in developing countries than among those in industrialized regions is not supported by the findings of one study that reported a mean CD4 cell count of 24 cells/mm 3 among African patients with AIDS who had PCP diagnosed while they were living in England [44] .
COINFECTION WITH MYCOBACTERIUM TUBERCULOSIS AND OTHER PATHOGENS
The percentage of individuals with PCP who are coinfected with other pathogens is higher in developing countries than in industrialized countries; rates of coinfection with any pathogen ranging from 20% to 70% have been reported (tables 1 and 2). Mycobacterium tuberculosis, which is the most common copathogen, is present in association with 13%-66% of cases of PCP (tables 1 and 2). One study from Mexico showed that tuberculosis was found at the time of postmortem examination of 24% of patients with AIDS, compared with 6% of US patients with AIDS and 5% of Italian patients with AIDS [33] . One report noted the frequency of coinfection with nontuberculous pathogens-for example, cytomegalovirus (68%), Streptococcus pneumoniae (50%), Staphylococcus aureus (25%), and Cryptococcus neoformans (25%). An autopsy report of children from Thailand [15] and another of adults from Taiwan [27] showed that 58% and 100% of patients with PCP, respectively, were coinfected with cytomegalovirus. Another autopsy series of 18 children from South Africa showed a high frequency of coinfection with cytomegalovirus (44%), which possibly reflected the low mean CD4 cell count (22 cells/mm 3 ) of the patients and the routine use of corticosteroids for the treatment of PCP [7] .
TREATMENT AND OUTCOME
No prospective, controlled treatment trial to assess the response of PCP to therapy has been performed in the developing world. Nevertheless, death is reported in association with the use of trimethoprim-sulfamethoxazole (TMP-SMX). Among adult patients in developing countries, the mortality rate ranges from 10% to 27%, a range similar to that reported in the United States. However, PCP-associated mortality rates among children in developing countries are higher than those among children in industrialized countries, ranging from 10% to 80% (table 1) . On the basis of the degree of oxygen exchange impairment provided in some reports, it is possible that the lower response rates may have been the result of late initiation of antipneumocystis treatment. Also, several antipneumocystis regimens that are alternatives to TMP-SMX therapy and that are used for individuals in industrialized nations who either are not responding to or are intolerant to TMP-SMX are not available in all developing countries. In addition, a more rapid progression of HIV infection may be an additional factor that contributes to mortality, because HAART was not available in developing countries at the time that the studies were conducted, and because the cause of death after diagnosis of PCP was not uniformly provided across studies. For example, death may have been due to an AIDS-associated complication other than PCP, including infection with M. tuberculosis or other copathogens.
CONCLUSIONS
PCP, which once was considered to be uncommon in the developing world, is now recognized as a significant AIDS-associated opportunistic infection in many developing countries. In contrast to reports from Africa issued in the early period of the pandemic, PCP now comprises a significant proportion of cases of respiratory symptoms in HIV-infected patients in Africa and in other regions in the developing world. The benefits of TMP-SMX prophylaxis demonstrated in 3 double-blind, placebo-controlled trials conducted in Africa are evidence of the clinical importance of PCP in the developing world. Two of these trials showed a reduction in the numbers of deaths and hospital admissions among patients with advanced HIV disease who were receiving TMP-SMX prophylaxis in Cote d'Ivoire [45] and South Africa [46] . A third trial, which included patients with an earlier stage of HIV infection, showed a reduction in morbidity but not in mortality, possibly because of the prevention of pathogens other than P. carinii, such as nontyphoidal salmonellae and S. pneumoniae [47] . In addition to those trials, the studies reviewed in this report support the World Health Organization/United Nations AIDS provisional recommendations for the use of TMP-SMX PCP chemoprophylaxis in developing regions of the world [48] . As has been witnessed in industrial countries, HIV and AIDS strategies that use PCP prophylaxis combined with HAART will likely reduce the significant prevalence of PCP in developing countries today.
